Ярослав Шпарик
Ярослав Шпарик
Lviv cancer center
Немає підтвердженої електронної адреси
НазваПосиланняРік
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
10622015
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
ME O'brien, TE Ciuleanu, H Tsekov, Y Shparyk, B Cuceviá, G Juhasz, ...
Journal of Clinical Oncology 24 (34), 5441-5447, 2006
4852006
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal …
JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 34 (5), 443-451, 2016
2152016
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, ...
The Lancet 388 (10063), 2997-3005, 2016
1982016
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The …
JR Hecht, YJ Bang, S Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 31 (18_suppl), LBA4001-LBA4001, 2013
1832013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial
A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, ...
Journal of Clinical Oncology 31 (10), 1341-1347, 2013
1082013
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
Cancer Research 74 (19 Supplement), CT101-CT101, 2014
642014
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled …
D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, ...
European journal of cancer 70, 146-155, 2017
552017
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2–advanced …
RS Finn, J Crown, I Lang, K Boer, I Bondarenko, SO Kulyk, J Ettl, R Patel, ...
Journal of Clinical Oncology 35 (15_suppl), 1001-1001, 2017
542017
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer
NK Ibrahim, KO Yariz, I Bondarenko, A Manikhas, V Semiglazov, ...
Clinical Cancer Research 17 (21), 6822-6830, 2011
442011
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
T Eisen, Y Shparyk, N Macleod, R Jones, G Wallenstein, G Temple, ...
Investigational new drugs 31 (5), 1283-1293, 2013
382013
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer …
HS Han, V Diéras, M Robson, M Palácová, PK Marcom, A Jager, ...
Annals of Oncology 29 (1), 154-161, 2017
372017
Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel …
YH Im, P Odarchenko, D Grecea, D Komov, CV Anatoliy, S Gupta, ...
Journal of Clinical Oncology 31 (15_suppl), 629-629, 2013
282013
Иммунологические механизмы естественной противоопухолевой резистентности
БТ Билынский, НА Володько, ЯВ Шпарык
Киев: Наукова думка 248, 1991
271991
O-157 survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC
M O'Brien, T Ciuleanu, H Tsekov, Y Shparyk, B Cucevic, G Juhasz, ...
Lung Cancer 49, S54, 2005
262005
A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Journal of Clinical Oncology, 2016
252016
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
HS Rugo, V Diéras, KA Gelmon, RS Finn, DJ Slamon, M Martin, P Neven, ...
Annals of Oncology 29 (4), 888-894, 2018
242018
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
232019
FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
MJ Ellis, I Bondarenko, E Trishkina, M Dvorkin, L Panasci, A Manikhas, ...
Annals of Oncology 27 (suppl_6), 2016
232016
Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients.
T Eisen, Y Shparyk, R Jones, NJ MacLeod, G Temple, H Finnigan, ...
Journal of Clinical Oncology 31 (15_suppl), 4506-4506, 2013
222013
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20